Literature DB >> 11187909

Extensive characterization of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro.

K Tarte1, G Fiol, J F Rossi, B Klein.   

Abstract

Dendritic cells (DC) play a key role in the initiation of primary immune response, and pilot clinical studies have demonstrated their ability to induce efficient antitumor immunity. However, the DC used in these clinical trials were generated with various serum sources and were poorly characterized. Obtaining fully characterized DC in controlled and reproducible culture conditions is thus of major interest. We demonstrate that X-VIVO 15 medium supplemented with 2% human albumin can be used to obtain DC. The phenotypic and functional characteristics of these clinical-grade DC were analyzed according to their differentiation stages. CD83 immature DC, obtained in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4, were able to endocyte soluble antigens and internalize apoptotic tumor cells, and also expressed receptors for inflammatory chemokines. Tumor necrosis factor-alpha (TNF-alpha) induced irreversible DC maturation in association with a decreased ability to uptake antigens and an increased allostimulatory capacity. CD83+ mature DC became responsive to EBI1 ligand chemokine (ELC), a chemokine specifically expressed in secondary lymphoid organs. In addition, mature DC obtained with TNF-alpha produced IL-12 and some IL-10 in response to CD40 stimulation. In conclusion, we present well-defined culture conditions allowing the control of DC maturation for clinical or fundamental studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11187909     DOI: 10.1038/sj.leu.2401925

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  10 in total

1.  Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.

Authors:  Michael Hundemer; Stefanie Schmidt; Maud Condomines; Alaviana Lupu; Dirk Hose; Marion Moos; Friedrich Cremer; Christian Kleist; Peter Terness; Sebastian Belle; Anthony D Ho; Hartmut Goldschmidt; Bernard Klein; Olaf Christensen
Journal:  Exp Hematol       Date:  2006-04       Impact factor: 3.084

2.  The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.

Authors:  Jérôme Moreaux; Friedrich W Cremer; Thierry Reme; Marc Raab; Karene Mahtouk; Philine Kaukel; Veronique Pantesco; John De Vos; Eric Jourdan; Anna Jauch; Eric Legouffe; Marion Moos; Genevieve Fiol; Hartmut Goldschmidt; Jean François Rossi; Dirk Hose; Bernard Klein
Journal:  Blood       Date:  2005-04-12       Impact factor: 22.113

3.  B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.

Authors:  Zhao-Yang Lu; Maud Condomines; Karin Tarte; Laure Nadal; Marie Claude Delteil; Jean François Rossi; Christophe Ferrand; Bernard Klein
Journal:  Exp Hematol       Date:  2007-03       Impact factor: 3.084

4.  Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.

Authors:  Karène Mahtouk; Dirk Hose; Pierre Raynaud; Michael Hundemer; Michel Jourdan; Eric Jourdan; Veronique Pantesco; Marion Baudard; John De Vos; Marion Larroque; Thomas Moehler; Jean-Francois Rossi; Thierry Rème; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2007-03-05       Impact factor: 22.113

5.  Dendritic cell-based assays, but not mannosylation of antigen, improves detection of T-cell responses to proinsulin in type 1 diabetes.

Authors:  Parth Narendran; Kathryn Elsegood; Nicola J Leech; Wallace M Macindoe; Geert-Jan Boons; Colin M Dayan
Journal:  Immunology       Date:  2004-04       Impact factor: 7.397

6.  Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma.

Authors:  Sebastian Belle; Fang Han; Maud Condomines; Olaf Christensen; Mathias Witzens-Harig; Bernd Kasper; Christian Kleist; Peter Terness; Marion Moos; Friedrich Cremer; Dirk Hose; Anthony D Ho; Hartmut Goldschmidt; Bernard Klein; Michael Hundemer
Journal:  Eur J Haematol       Date:  2008-03-19       Impact factor: 2.997

Review 7.  Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells.

Authors:  Jean-François Rossi; Patrice Céballos; Zhao-Yang Lu
Journal:  Cancer Commun (Lond)       Date:  2019-06-14

8.  Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.

Authors:  Sylvia Janetzki; L Price; C M Britten; S H van der Burg; J Caterini; J R Currier; G Ferrari; C Gouttefangeas; P Hayes; E Kaempgen; V Lennerz; K Nihlmark; V Souza; A Hoos
Journal:  Cancer Immunol Immunother       Date:  2009-11-06       Impact factor: 6.968

9.  Interferon-gamma Added During Bacillus Calmette-Guerin Induced Dendritic Cell Maturation Stimulates Potent Th1 Immune Responses.

Authors:  Gopi Shankar; Linda A Pestano; Marnix L Bosch
Journal:  J Transl Med       Date:  2003-10-10       Impact factor: 5.531

10.  Restoration of MYC-repressed targets mediates the negative effects of GM-CSF on RUNX1-ETO leukemogenicity.

Authors:  S Weng; S Matsuura; C T Mowery; S A Stoner; K Lam; D Ran; A G Davis; M-C Lo; D-E Zhang
Journal:  Leukemia       Date:  2016-06-15       Impact factor: 11.528

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.